Palvella Therapeutics (Nasdaq: PVLA) announced it has submitted the first module of a rolling New Drug Application (NDA) to the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE